Delivers the Most Accurate Data for Comprehensive Cancer Studies Performed by the Illumina Genome Network
SAN DIEGO--(BUSINESS WIRE)--Feb. 16, 2012-- Illumina, Inc. (NASDAQ:ILMN) today announced the launch of a Cancer Analysis Service from the Illumina Genome Network (IGN) that leverages the high accuracy of Illumina technologies to provide cancer researchers with easily interpretable tumor/normal sequencing data to quickly move their research forward. IGN is designed to link researchers needing large-scale, whole human genome sequencing services with leading institutions that provide these services using industry-leading Illumina sequencing platforms powered by TruSeq® technology.
Due to the lowest sample input volume of any commercial whole human genome sequencing service (5 μg), the IGN Cancer Analysis Service enables researchers to add the greatest number of samples to their studies. By better modeling the impurities of real-life tumor extracts, IGN’s optimized combined calling analysis method yields the most accurate somatic mutation calls, recovering 97% of known SNVs (versus 77% using subtractive analysis methods), even when tumor purity is low (<40%).
“Researchers can trust the quality of IGN data and confidently take the next step in their research,” said Scott Kahn, Vice President and Chief Information Officer at Illumina. “High data accuracy and our unique ability to integrate data from transcriptome or methylome studies will allow researchers to gain a deeper understanding of cancer mechanisms.”
In addition to its Cancer Analysis Services, Illumina is working with leading data analysis and visualization companies, including Diagnomics, Ingenuity, and Knome, to provide optimized software tools for downstream filtering and interrogation of IGN datasets, with a goal of delivering biologically relevant and actionable results. The data can also be integrated with the results of follow-on sequencing, genotyping, and RNA-Seq studies performed to help researchers better understand cancer and the biological pathways it impacts.
All IGN partners are experienced with Illumina TruSeq™ technology and have completed CSPro certification. Each possesses ten or more Illumina sequencing systems (HiSeq systems and/or Genome Analyzers), providing the scalability to handle even the largest sequencing projects with rapid turnaround times. IGN members include the British Columbia Cancer Agency’s Genome Science Centre, University of Washington Department of Genome Sciences, National Center for Genome Resources, Macrogen/Genomic Medicine Institute, and Illumina’s own FastTrack Services.
For more information, please visit http://www.illumina.com/IGN.
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
Forward-Looking Statements
This release contains forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
Source: Illumina, Inc.
Illumina, Inc.
Investors:
Kevin Williams, MD
Investor Relations
858-332-4989
kwilliams@illumina.com
or
Media:
Laura Trotter
Public Relations
858-882-6822
pr@illumina.com
